US-based external-beam theranostic oncology company, RefleXion, has announced that its radiotherapy device RefleXion X1 has been used as part of a worlds first combination of therapies including biology-guided radiotherapy and Stereotactic Body Radiation Therapy (SBRT).

The company says that its multi-target treatment (MTT) system, the company’s most recent upgrade for its RefleXion X1 platform allows clinicians to combine Scintix’s biology-guided radiotherapy, designed to target tumors in lungs or bones, with more traditional SBRT treatment for tumors across the body.

RefleXion revealed  that Connecticut’s Yale New Haven Heath has for the first time treated a patient using the combination therapy using the company’s radiotherapy system which RefleXion says is able to integrate real-time data into treatment to account for things such as patient movement.

Chief of the Biology-guided Radiotherapy Program at Yale Medical School, Henry Park, said: “By integrating different treatment modalities within the same plan, we can tailor the optimal treatment approach to each tumor.

“In this patient, SCINTIX therapy treated the moving lung tumor, while SBRT targeted a static tumor elsewhere. It was equally groundbreaking to visually confirm that the SCINTIX treatment responded to the tumor’s motion and delivered the dose precisely as planned. With conventional radiotherapy, once treatment commences, there is no visual assurance of what is happening inside the patient.”

The announcement follows after RefleXion Medical signed a number of licencing agreements with companies such as Limbus AI for its Limbus Contour software in March 2024, and Mirada Medical in 2022 to include their respective software systems to further build out the multi-modal options of its X1 device. RefleXion claims that the ability to monitor real-time data, which has never been possible before, ensures that Scintix treatment is progressing as expected and that the entire hybrid MTT plan is delivered in five or fewer sessions.